<!– –> <!– Page Last Updated: 03/02/2012 –> Page Last Updated: 03/02/2012 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Safety tips for intense pulsed light therapy
By Eileen Woo, BSN, RN, and Jitendra Virani, MS (Article originally published in Nursing2012, February issue.) INTENSE PULSED LIGHT (IPL) therapy is indicated for use in surgical, aesthetic, and cosmetic applications.1 IPLs use flashlamps, computer-controlled power supplies, and bandpass filters to generate light pulses of prescribed duration, intensity, and spectral distribution. The light energy is…
Statins and HIV or Hepatitis C Drugs: Drug Safety Communication
<!– –> <!– Page Last Updated: 03/01/2012 –> Page Last Updated: 03/01/2012 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Updated Questions and Answers for Healthcare Professionals and the Public: Use an Approved Pancreatic Enzyme Product (PEP)
[3/1/2012] This set of Questions and Answers was originally posted on April 12, 2010, and updated on May 24, 2010 and March 1, 2012. It is being updated to provide additional information to healthcare professionals and the public about the safe use of approved pancreatic enzyme products. Q1. What are pancreatic enzyme products? Q2. Why has…
FDA Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury
Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData SummaryStatin Dose Limitations Reference  Infographic About Cholesterol and Statins Safety Announcement [3-01-2012] The U.S. Food and Drug Administration (FDA) is issuing updated recommendations concerning drug-drug interactions between drugs for human immunodeficiency virus (HIV) or hepatitis C virus (HCV) known as protease inhibitors and certain cholesterol-lowering drugs…
Evaluation of Automatic Class III Designation (De Novo) Decision : K103039 added
<!– –> <!– Page Last Updated: 02/29/2012 –> Page Last Updated: 02/29/2012 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.